证券日报网讯1月20日，昭衍新药（603127）在互动平台回答投资者提问时表示，公司具备OECD的 GLP认证资质，可以承接相关非临床服务项目，但来自欧盟地区的收入占比极低，不构成重要影响。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of approximately RMB 233 million to RMB 349 million for the year 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1: Financial Performance - The increase in fair value is driven by a rise in market prices of biological assets and natural growth appreciation [1] - The laboratory operations have maintained a stable performance during the reporting period [1] Group 2: Revenue and Profitability - Due to the previous intense industry competition, the revenue and gross margin from performance contracts have decreased year-on-year [1] - The contribution of laboratory service business profits has declined [1]

证券代码：603127 证券简称：昭衍新药 公告编号：2026-003 北京昭衍新药研究中心股份有限公司 2025 年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 适用情形：实现盈利，且净利润与上年同期相比上升 50%以上 1. 预 计 2025 年 实 现 营 业 收 入 约 人 民 币 157,259.91 万 元 到 人 民 币 173,813.58 万元，与上年同期的数据相比，将减少约人民币 28,019.80 万元到 人民币 44,573.47 万元，同比减少约 13.9%到 22.1%。 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 公司财务部门初步测算如下： 1. 预 计 2025 年 实 现 营 业 收 入 约 人 民 币 157,259.91 万 元 到 人 民 币 173,813.58 万元，与上年同期的数据相比，将减少约人民币 28,019.80 万元到 人民币 44,573.47 万元，同比减少约 13.9%到 22.1%。 ...

格隆汇1月20日丨昭衍新药(603127.SH)公布，预计2025年实现营业收入约人民币15.73亿元到人民币 17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80 万元到人民币 44,573.47 万元，同比减少 约 13.9%到 22.1%。 预计2025年实现归属于上市公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据 相比，将增加约人民币15,853.52万元到人民币 27,484.06万元，同比增加约214.0%到371.0%。 预计 2025 年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币 24,638.00 万元到人民币 36,956.99 万元，与上年同期的数据相比，将增加约人民币 22,280.66 万元到人民币 34,599.65 万元，同 比增加约945.2%到1,467.7%。 ...

预计2025年实现归属于上市公司股东的净利润约人民币2.33亿元到人民币3.49亿元，与上年同期的数据 相比，将增加约人民币15,853.52万元到人民币 27,484.06万元，同比增加约214.0%到371.0%。 预计 2025 年实现归属于上市公司股东的扣除非经常性损益的净利润约人民币 24,638.00 万元到人民币 36,956.99 万元，与上年同期的数据相比，将增加约人民币 22,280.66 万元到人民币 34,599.65 万元，同 比增加约945.2%到1,467.7%。 格隆汇1月20日丨昭衍新药(603127.SH)公布，预计2025年实现营业收入约人民币15.73亿元到人民币 17.38亿元，与上年同期的数据相比，将减少约人民币28,019.80 万元到人民币 44,573.47 万元，同比减少 约 13.9%到 22.1%。 ...

Core Viewpoint - Zhaoyan New Drug (603127.SH) forecasts a net profit attributable to shareholders of 233 million to 349 million yuan for the fiscal year 2025, representing a year-on-year growth of 214.0% to 371.0% [1] Group 1 - The increase in profit is driven by rising market prices of biological assets and natural growth appreciation, leading to positive fair value changes [1]

Core Viewpoint - Zhaoyan New Drug (603127) expects a net profit attributable to shareholders of approximately 233 million to 349 million yuan in 2025, representing a year-on-year increase of about 214% to 371% [1] Group 1 - The increase in net profit is driven by the rise in market prices of biological assets and the natural growth appreciation of the assets [1] - The dual factors of market price increase and asset appreciation contribute positively to the company's performance [1]

Core Viewpoint - Zhaoyan New Drug has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven by rising market prices of biological assets and stable laboratory operations [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 232.61 million to 348.92 million yuan for 2025, representing a year-on-year increase of 214.00% to 371.00% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 246.38 million to 369.57 million yuan, with a year-on-year growth of 945.20% to 1,467.70% [1] Group 2: Contributing Factors - The increase in fair value of biological assets is attributed to both rising market prices and natural growth, positively impacting the company's performance [1] - Despite maintaining stable operations in the laboratory, the company experienced a decline in revenue and gross margin from performance contracts due to previous intense industry competition, leading to a decrease in profit contribution from laboratory services [1]

Core Viewpoint - The company expects a significant increase in net profit attributable to shareholders for 2025, projecting between RMB 233 million and RMB 349 million, which represents a year-on-year increase of approximately 214.0% to 371.0% compared to the previous year [1] Financial Performance - The projected net profit increase is expected to be between RMB 159 million and RMB 275 million compared to the same period last year [1] - The growth in fair value is driven by a combination of rising market prices for biological assets and natural growth appreciation [1]

Group 1 - On January 16, Zhaoyan New Drug experienced a decline of 1.84% with a trading volume of 673 million yuan, and the net financing buy was -7.46 million yuan [1] - As of January 16, the total balance of margin trading for Zhaoyan New Drug was 420 million yuan, with a financing balance of 415 million yuan, accounting for 1.56% of the circulating market value, which is below the 50th percentile level over the past year [1] - The company primarily engages in non-clinical safety evaluation services for drugs, with 95.59% of its main business revenue derived from non-clinical research services [1] Group 2 - As of September 30, the number of shareholders for Zhaoyan New Drug increased by 57.61% to 96,500, while the average circulating shares per person remained at 0 [2] - For the period from January to September 2025, Zhaoyan New Drug reported an operating income of 985 million yuan, a year-on-year decrease of 26.23%, while the net profit attributable to the parent company was 80.71 million yuan, reflecting a year-on-year increase of 214.79% [2] - The company has distributed a total of 703 million yuan in dividends since its A-share listing, with 356 million yuan distributed over the past three years [3]